Rapamycin: Rapamycin Holdings Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer

Firstever human use of eRapa in clinical trial at UT Health San Antonio MD Anderson Cancer Center will test safety effective dose and tolerability in earlystage prostate cancer patients and explore how the drug could boost the immun...